L9LS MAb in Malian Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

490

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

February 11, 2024

Study Completion Date

February 11, 2024

Conditions
Plasmodium Falciparum InfectionMalaria
Interventions
BIOLOGICAL

L9LS (VRC-MALMAB0114-00-AB)

Administered one time via subcutaneous route.

OTHER

Placebo

Normal saline administered one time via subcutaneous route.

Trial Locations (3)

Unknown

Faladje MRTC Clinic, Faladiè

Kalifabougou MRTC Clinic, Kalifabougou

Torodo MRTC Clinic, Torodo

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

University of the Sciences, Techniques and Technologies of Bamako

OTHER

collaborator

University of Washington

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Indiana University School of Medicine

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05816330 - L9LS MAb in Malian Adults | Biotech Hunter | Biotech Hunter